)
Rachel Liberatore
President & Chief Scientific Officer,
RenBio
Dr. Rachel Liberatore is the President and Chief Scientific Officer at RenBio, a biotechnology company in New York developing a platform technology for the DNA-based delivery of monoclonal antibodies and therapeutic proteins. Previously, as a postdoctoral fellow at the Aaron Diamond AIDS Research Center, she used genetic techniques to understand how intrinsic cellular defenses restrict the spreading of retroviruses, including HIV-1. She also studied the elicitation of antiviral antibodies directed at viral envelope proteins. Dr. Liberatore received her bachelor’s degree in Molecular Biology from Princeton University and her Ph.D. in Cellular, Molecular, and Biomedical Studies from Columbia University.